What Can the Pharma Industry Learn from Merck’s New Antiviral?

 

Merck is one of the first pharmaceutical companies to submit an antiviral candidate to the FDA for approval, signaling the beginning of a new phase of mass production of COVID treatment drugs. For Merck’s oral antiviral, molnupiravir, its optimistic success can be largely credited to its federal funding. Work on the related compound was active at Emory University as far back as 2004, with millions

With that kind of federal investment, and Operation Warp Speed validating the role of the federal government in supporting critical biomedical development, we wanted to know: can the industry expect any further involvement, financial or regulatory, from the federal government around COVID treatments? Plus, as Operation Warp Speed accelerated the COVID vaccine research timeline, are there more sustainable ways to bring this level of turnaround to other parts of the pharmaceutical pipeline without lags in treatment quality or oversight?

MarketScale sourced Dr. Kishor M. Wasan, Chief Medical and Scientific Officer at Skymount Medical, for his perspective, pulling from his active research around drug production and AI. Scroll down for his various insights!

1. Do the Successes of Operation Warp Speed Validate the Support of the Federal Government?

 

2. How LSU Designed a Model to Speed Up the Evaluation of Drug Candidates

 

3. How the Pharmaceutical Pipeline can Balance Speed and Quality

 

Follow us on social media for the latest updates in B2B!

Latest

Bluedot’s Report Offers Restaurants Insight Into Consumer Spending Behaviors
September 23, 2022
Inflation and ongoing concerns of a recession are affecting consumer spending behaviors. And as always, the restaurant industry is a great place to take the temperature of what people are willing to Read more
Advancements in Bone Health Imaging with Dr. Ego Seeman
September 23, 2022
  CurveBeam AI Medical Director - Endocrinology Prof. Ego Seeman recently sat down with Vinti Singh, CurveBeam AI’s Marketing Director, to discuss the future of bone health imaging. Prof. Seeman is a Read more
OT and IT Edge Convergence and the Emergence of the Edge Marketplace
OT and IT Edge Convergence and the Emergence of the Edge Marketplace
September 23, 2022
To win the edge ecosystem game, it will take a village approach. Edge is no longer a linear value chain, going from step to step. An emerging circular value chain, with an open and extendable Read more